169 related articles for article (PubMed ID: 33907118)
1. Can YKL-40 be used as a biomarker for interstitial lung disease?: A systematic review and meta-analysis.
Tong X; Ma Y; Liu T; Li Z; Liu S; Wu G; Fan H
Medicine (Baltimore); 2021 Apr; 100(17):e25631. PubMed ID: 33907118
[TBL] [Abstract][Full Text] [Related]
2. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
Hozumi H; Fujisawa T; Enomoto N; Nakashima R; Enomoto Y; Suzuki Y; Kono M; Karayama M; Furuhashi K; Murakami A; Inui N; Nakamura Y; Mimori T; Suda T
J Rheumatol; 2017 Sep; 44(9):1394-1401. PubMed ID: 28711881
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias.
Korthagen NM; van Moorsel CH; Zanen P; Ruven HJ; Grutters JC
Lung; 2014 Dec; 192(6):975-80. PubMed ID: 25274153
[TBL] [Abstract][Full Text] [Related]
4. [Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury].
Zhang PL; Yang HX; Zhang LN; Ge YP; Peng QL; Wang GC; Lu X
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1055-1060. PubMed ID: 34916681
[TBL] [Abstract][Full Text] [Related]
5. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
6. Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis.
Korthagen NM; van Moorsel CH; Barlo NP; Ruven HJ; Kruit A; Heron M; van den Bosch JM; Grutters JC
Respir Med; 2011 Jan; 105(1):106-13. PubMed ID: 20888745
[TBL] [Abstract][Full Text] [Related]
7. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis.
Bonella F; Long X; He X; Ohshimo S; Griese M; Guzman J; Costabel U
Respirology; 2017 Oct; 22(7):1371-1378. PubMed ID: 28569052
[TBL] [Abstract][Full Text] [Related]
8. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis.
Long X; He X; Ohshimo S; Griese M; Sarria R; Guzman J; Costabel U; Bonella F
Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 27836954
[TBL] [Abstract][Full Text] [Related]
9. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
10. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review.
Tong X; Wang D; Liu S; Ma Y; Li Z; Tian P; Fan H
Int J Chron Obstruct Pulmon Dis; 2018; 13():409-418. PubMed ID: 29430175
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of YKL-40 in patients with polymyositis/dermatomyositis: A cross-sectional study and a systematic review.
Cui B; Chen Y; Luo F; Lin S; Liu H; Huang Y; Zhou Y; Tian Y; Yin G; Xie Q
J Clin Lab Anal; 2022 Sep; 36(9):e24605. PubMed ID: 35837962
[TBL] [Abstract][Full Text] [Related]
12. Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.
Hamada T; Samukawa T; Kumamoto T; Hatanaka K; Tsukuya G; Yamamoto M; Machida K; Watanabe M; Mizuno K; Higashimoto I; Inoue Y; Inoue H
BMC Pulm Med; 2015 Sep; 15():110. PubMed ID: 26424433
[TBL] [Abstract][Full Text] [Related]
13. MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases.
Korthagen NM; Nagtegaal MM; van Moorsel CH; Kazemier KM; van den Bosch JM; Grutters JC
Clin Exp Immunol; 2010 Aug; 161(2):342-7. PubMed ID: 20550547
[TBL] [Abstract][Full Text] [Related]
14. Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis.
Bennett D; Bargagli E; Bianchi N; Landi C; Fossi A; Fui A; Sestini P; Refini RM; Rottoli P
Respir Physiol Neurobiol; 2020 Feb; 273():103323. PubMed ID: 31678459
[TBL] [Abstract][Full Text] [Related]
15. CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features.
Kameda M; Otsuka M; Chiba H; Kuronuma K; Hasegawa T; Takahashi H; Takahashi H
PLoS One; 2020; 15(11):e0241719. PubMed ID: 33137121
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis.
Furuhashi K; Suda T; Nakamura Y; Inui N; Hashimoto D; Miwa S; Hayakawa H; Kusagaya H; Nakano Y; Nakamura H; Chida K
Respir Med; 2010 Aug; 104(8):1204-10. PubMed ID: 20347285
[TBL] [Abstract][Full Text] [Related]
17. YKL-40 and KL-6 Levels in Serum and Sputum of Patients Diagnosed With Hypersensitivity Pneumonitis.
Sánchez-Díez S; Munoz X; Ojanguren I; Romero-Mesones C; Espejo D; Villar A; Gómez-Olles S; Cruz MJ
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2414-2423. PubMed ID: 35788062
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical courses and mortality of connective tissue disease-associated interstitial pneumonias and chronic fibrosing idiopathic interstitial pneumonias.
Yıldırım F; Türk M; Bitik B; Erbaş G; Köktürk N; Haznedaroğlu Ş; Türktaş H
Kaohsiung J Med Sci; 2019 Jun; 35(6):365-372. PubMed ID: 30913371
[TBL] [Abstract][Full Text] [Related]
19. Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases.
Bergantini L; d'Alessandro M; Cameli P; Perrone A; Cekorja B; Boncompagni B; Mazzei MA; Sestini P; Bargagli E
Eur J Intern Med; 2021 Jul; 89():76-80. PubMed ID: 33931268
[TBL] [Abstract][Full Text] [Related]
20. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases.
Nakashima T; Omori K; Namba M; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Respir Med; 2023 Jun; 212():107224. PubMed ID: 37003499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
